As previously discussed here, the California bill that would have allowed physcicians to block any substitution of biosimilars for the original biologic (as well as required reporting for any substitution) was vetoed by Governor Brown.
The bill in California was being closely watched because the state is not only large, but is often seen as a bellwether for pharmacy practice. Moreover, Amgen and Genentech, a unit of Roche, are both based in California, and so their lobbying campaign for the bill was viewed, by some, as a litmus test for their political influence.
In explaining his decision, Brown wrote that he strongly supports allowing interchangeable biosimilars to be substituted for biologics, but noted the FDA has not yet "determined what standards will be required for biosimilars to meet the higher threshold for interchangeability. Given this fact, to require physician notification at this point strikes me as premature".
The generics manufacturers (GPhA), various patient advocate organizations, Pharmacists associations and National Drug Chains generally were supportive of the veto. Amgen and Genentech would just as soon the legistlation had passed, and BIO was also a backer of the bill. See Pharmalot.
Posted by Bruce Lehr Oct 15th 2013.